Pre-clinical, Results

That biotech unicorn you (pick love or hate) just spotlighted some intriguing mouse (yes) data on a triple mRNA cancer therapy

The cancer team working under Moderna’s Tal Zaks have been tinkering with various combinations of mRNA in mice to see how best they can use this technology to orchestrate an immune system attack. And today they’re highlighting a preclinical rodent study that indicates they could be on a promising path that’s taken them into human trials.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 45,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->